uniQure NV (uniQure NV) Short Interest

View and export this data going back to 2014. Start your Free Trial

What is uniQure NV Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of uniQure NV's Short Interest

For the Biotechnology subindustry, uniQure NV's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

uniQure NV's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's Short Interest distribution charts can be found below:

* The bar in red indicates where uniQure NV's Short Interest falls into.

uniQure NV (uniQure NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (NAS:QURE) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

UQ1:Germany UQ1:Germany

Address

Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP

Website

https://www.uniqure.com

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Executives

Walid Abi-saab	officer: Chief Medical Officer	C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 11058BP
Ricardo Dolmetsch	officer: President, R&D	113 HARTWELL AVENUE, LEXINGTON MA 02421
Pierre Caloz	officer: Chief Operating Officer	UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 P7 11058BP
Madhavan Balachandran	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rachelle Suzanne Jacques	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Gut	director	C/O VERSARTIS, INC., 4200 BOHANNON DRIVE, SUITE 250, MENLO PARK CA 94025
Leonard E Post	director
Christian Klemt	officer: Chief Financial Officer	PAASHEUVELWEG 25A, AMSTERDAM P7 1105 BP
Jack Kaye	director	C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Jeremy P. Springhorn	director	C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421
David D. Meek	director	3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Paula Soteropoulos	director	49 WINONA STREET, PEABODY MA 01960
Jeannette Potts	officer: See Remarks	C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Matthew C Kapusta	director, officer: CEO, Managing Director	7358 MCVAY ROAD, GERMANTOWN TN 38138
Kuta Alexander Edward Iii	officer: Executive VP, Operations	239 WILLIS ROAD, SUDBURY MA 01776